Clinical trial
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced…
NCT00244972 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00244972 |
|---|---|
| Title | Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer |
| Official title | Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Malignant Neoplasm |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Sorafenib Tosylate, Tipifarnib |
| Enrollment | 74 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2017 |
| Completion | Mar 1, 2017 |
| First posted | Oct 27, 2005 |
| Last update posted | Apr 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: